Blueprint Medicines is a biopharmaceutical company with a singular focus on eradicating genomically defined cancers and rare diseases. Our goal is to develop transformational medicines using our world-leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and development of new treatments and increases the likelihood of clinical success. In addition to multiple research programs, we are currently advancing three investigational medicines in clinical development for subsets of patients with gastrointestinal stromal tumors, systemic mastocytosis, hepatocellular carcinoma, non-small cell lung cancer, medullary thyroid cancer, and other genomically defined cancers.

Explore our website to see how we’re creating a blueprint for a healthier tomorrow.